人胃癌次黄嘌呤-鸟便嘌呤磷酸核糖转移酶缺陷株的建立

THE ESTABLISHMENT OF HGPRT MUTANT FROM HUMAN STOMACH GLANDULAR CARCINOMA(BGC 823)

本研究首先用化学突变剂MNNG处理人胃癌细胞系(BGC 823),以提高突变率。然后用递增浓度的鸟便嘌呤类似物8-AG选择次黄嘌呤-鸟便嘌呤磷酸核糖转移酶(HGPRT)缺陷细胞,8-AG递增浓度为1~20μg/ml,历时半年。获得抗8-AG毒性的突变细胞,在HAT培养基中不能生存。经HGPRT酶的同位素法测定,发现野生型与突变型的BGC 823细胞有明显差别。本文还对缺陷型BGC 823的A、B、C、D、E、F株的应用进行了讨论。

The wild type cells of human stomach glandular carcinoma,cell line BGC 823,were treated firstly by a chemical carcinogen(MNNG)for the induction of mutagenesis,then the cells were selected in medium with gradually increasing amount of 8-AG(8-azaguanine)from 1-20μg/ml.It was found that the mutant cells could grow vigorously in the medium containing 20μg/ml of 8-AG but not in HAT medium.The HGPRT assay showed an obvious quantitative difference between the wild type and HGPRT mutant cells of BGC 823.